According to a new poll, even the U.S. federal government is more well-liked by Americans than the pharmaceutical industry.
All eyes were on Oklahoma last week, when the first case in a flood of litigation against opioid drug manufacturers began Tuesday.
Of the roughly $23.3 billion in sales growth seen by 45 top pharmaceutical products, $14.3 billion of that has been tied to price increases, not demand.
An in-depth look at a recent paper that explores correlational data relating opioid prescribing to opioid manufacturer payments.
The pharmaceutical industry fears major legislation that would curb prices and shrink profits, and has launched campaigns against it—but how honest are their claims?
Recent lawsuits are asking courts whether the current crisis is comparable to the one over tobacco in the ’90s.